Patents by Inventor Francois-Loic Cosset
Francois-Loic Cosset has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230348934Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.Type: ApplicationFiled: March 6, 2023Publication date: November 2, 2023Applicants: Ecole Normale Superieure de Lyon, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Institut National de la Santé et de la Recherche Medicale (INSERM), Centre National de la Recherche ScientifiqueInventors: Caroline COSTA FEJOZ, Els Verhoeyen, François-Loîc Cosset, Ruben Bender, Christian Buchholz, Qi Zhou
-
Publication number: 20230340085Abstract: The invention concerns a multicistronic nucleic acid, in particular an isolated multicistronic nucleic acid, comprising: A) a sequence comprising successively: A1) a sequence encoding the light chain variable domain of an antibody of interest, fused in the frame with A2) a sequence encoding the constant region of the light chain of an immunoglobulin Ig; and B) a sequence compris -ing successively: B1) a sequence encoding the heavy chain variable domain of said antibody of interest, fused in the frame with B2) a sequence encoding the constant regions of the heavy chain of an immunoglobulin Ig? in secretory form; B3) an intronic sequence of the gene of the heavy chain of said immunoglobulin Ig?, said intronic sequence comprising an internal 5? splice site enabling the spli -cing of said intronic sequence B3) and a secretory-specific poly(A) (p AS) signal from the 3? terminal exon of said gene; B4) a se -quence, in frame with sequence B1), encoding the transmembrane and cytoplasmic domains M1 and M2 of the immunType: ApplicationFiled: February 24, 2023Publication date: October 26, 2023Inventors: Floriane FUSIL, Els VERHOEYEN, Thierry DEFRANCE, François-Loïc COSSET
-
Patent number: 11623950Abstract: The invention concerns a multicistronic nucleic acid, in particular an isolated multicistronic nucleic acid, comprising: A) a sequence comprising successively: A1) a sequence encoding the light chain variable domain of an antibody of interest, fused in the frame with A2) a sequence encoding the constant region of the light chain of an immunoglobulin Ig; and B) a sequence comprising successively: B1) a sequence encoding the heavy chain variable domain of said antibody of interest, fused in the frame with B2) a sequence encoding the constant regions of the heavy chain of an immunoglobulin Ig? in secretory form; B3) an intronic sequence of the gene of the heavy chain of said immunoglobulin Ig?, said intronic sequence comprising an internal 5? splice site enabling the splicing of said intronic sequence B3) and a secretory-specific poly(A) (p AS) signal from the 3? terminal exon of said gene; B4) a sequence, in frame with sequence B1), encoding the transmembrane and cytoplasmic domains M1 and M2 of the immunoglobuType: GrantFiled: July 8, 2016Date of Patent: April 11, 2023Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE NORMALE SUPERIEURE DE LYONInventors: Floriane Fusil, Els Verhoeyen, Thierry Defrance, François-Loïc Cosset
-
Patent number: 11608509Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.Type: GrantFiled: April 20, 2017Date of Patent: March 21, 2023Assignees: Ecole Normale Superieure de Lyon, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Caroline Costa Fejoz, Els Verhoeyen, François-Loïc Cosset, Ruben Bender, Christian Buchholz, Qi Zhou
-
Publication number: 20190144885Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.Type: ApplicationFiled: April 20, 2017Publication date: May 16, 2019Applicants: Ecole Normale Superieure de Lyon, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Institut National de la Sante et de la Recherche M edicale (INSERM)Inventors: Caroline Costa Fejoz, Els Verhoeyen, François-Loïc Cosset, Ruben Bender, Christian Buchholz, Qi Zhou
-
Publication number: 20180371064Abstract: The invention concerns a multicistronic nucleic acid, in particular an isolated multicistronic nucleic acid, comprising: A) a sequence comprising successively: A1) a sequence encoding the light chain variable domain of an antibody of interest, fused in the frame with A2) a sequence encoding the constant region of the light chain of an immunoglobulin Ig; and B) a sequence comprising successively: B1) a sequence encoding the heavy chain variable domain of said antibody of interest, fused in the frame with B2) a sequence encoding the constant regions of the heavy chain of an immunoglobulin Ig? in secretory form; B3) an intronic sequence of the gene of the heavy chain of said immunoglobulin Ig?, said intronic sequence comprising an internal 5? splice site enabling the splicing of said intronic sequence B3) and a secretory-specific poly(A) (p AS) signal from the 3? terminal exon of said gene; B4) a sequence, in frame with sequence B1), encoding the transmembrane and cytoplasmic domains M1 and M2 of the immunoglobuType: ApplicationFiled: July 8, 2016Publication date: December 27, 2018Inventors: Floriane FUSIL, Els VERHOEYEN, Thierry DEFRANCE, François-Loïc COSSET
-
Patent number: 9765304Abstract: The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.Type: GrantFiled: January 24, 2014Date of Patent: September 19, 2017Assignee: L'Universite Pierre Et Marie CurieInventors: David Klatzmann, Jean-Loup Salzmann, Bertrand Bellier, Charlotte Fribert, Francois-Loic Cosset
-
Patent number: 9714434Abstract: The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, and a second protein which comprises a ligand of the c-Kit receptor.Type: GrantFiled: June 10, 2013Date of Patent: July 25, 2017Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Francois-Loic Cosset, Els Verhoeyen, Caroline Costa, Cecilia Frecha
-
Publication number: 20160193325Abstract: The invention relates to the generation and the use of hepacivirus pseudo-particles containing native functional E1, E2 envelope glycoproteins assembled onto retroviral core particles. These particles are highly infectious and constitute a valid model of hepacivirus virion.Type: ApplicationFiled: March 10, 2016Publication date: July 7, 2016Inventors: Birke Bartosch, Francois-Loic Cosset
-
Patent number: 9249426Abstract: The present invention concerns a pseudotyped viral vector particle for transferring biological material into cells, wherein said vector particle comprises at least:—a chimeric envelope glycoprotein which comprises or consists in a fusion of the transmembrane and extracellular domain of a baboon endogenous retrovirus (BaEV) envelope glycoprotein and the cytoplasmic tail domain of a murine leukemia virus (MLV) envelope glycoprotein; or—a modified BaEV envelope glycoprotein wherein the cytoplasmic tail domain is devoid of the fusion inhibitory R peptide.Type: GrantFiled: September 28, 2012Date of Patent: February 2, 2016Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Ecole Normale Superieur de LyonInventors: Anais Girard-Gagnepain, Els Verhoeyen, Dimitri Lavillette, Francois-Loic Cosset
-
Patent number: 9090908Abstract: A method is provided for producing a recombinant pseudotyped viral vector particle wherein a cell is transfecting with (i) at least one vector construct; (ii) at least one packaging construct; and (iii) an expression construct encoding a chimeric glycoprotein encoded by a nucleic acid comprising the sequence of SEQ ID NO: 1 to yield a producer cell, followed by culturing the producer cell in a medium; and separating the producer cell from the medium to recover the recombinant viral vector particle from the medium. Vectors obtained in this manner have significantly higher titers than vectors coated with the parental non-chimeric glycoprotein.Type: GrantFiled: November 14, 2012Date of Patent: July 28, 2015Assignees: INSTITUT NATIONAL DE LA RECHERCHE MEDICALE (INSERM), INSTITUT CLAYTON DE LA RECHERCHEInventors: Didier Trono, Francois-Loic Cosset, Virginie Sandrin
-
Patent number: 9011939Abstract: The present invention relates to polysaccharides selected from sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans intended to be used as a drug for the preventive or curative treatment of an influenza virus, as well as to the pharmaceutical compositions including, in particular in combination with at least one pharmaceutically acceptable carrier: either an extract of Codium fragile, including sulphated arabinogalactans, or an extract of Zostera marina or Lemna minor, including apiogalacturonans, or an extract of Caulerpa racemosa, including sulphated heteroglycans.Type: GrantFiled: January 3, 2012Date of Patent: April 21, 2015Assignees: Elicityl, Centre National de la Recherche Scientifique, Insititut National de la Sante et de la Recherche Medicale—I.N.S.E.R.M., Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA)Inventors: Bruno Lina, Olivier Ferraris, Ho Hong Hai Vo, François-Loïc Cosset, Judit Szecsi, Alain Heyraud, Hugues Lortat-Jacob, Julia Bartoli, Rabia Sadir, Thierry Livache, Benoît Darblade, Stéphane Havet, Silvère Bonnet
-
Publication number: 20140255445Abstract: The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.Type: ApplicationFiled: January 24, 2014Publication date: September 11, 2014Applicant: L'Universite Pierre Et Marie CurieInventors: David Klatzmann, Jean-Loup Salzmann, Bertrand Bellier, Charlotte Frisen, Francois-Loic Cosset
-
Publication number: 20140235700Abstract: The present invention concerns a pseudotyped viral vector particle for transferring biological material into cells, wherein said vector particle comprises at least:—a chimeric envelope glycoprotein which comprises or consists in a fusion of the transmembrane and extracellular domain of a baboon endogenous retrovirus (BaEV) envelope glycoprotein and the cytoplasmic tail domain of a murine leukemia virus (MLV) envelope glycoprotein; or—a modified BaEV envelope glycoprotein wherein the cytoplasmic tail domain is devoid of the fusion inhibitory R peptide.Type: ApplicationFiled: September 28, 2012Publication date: August 21, 2014Inventors: Anais Girard-Gagnepain, Els Verhoeyen, Dimitri Lavillette, François-Loïc Cosset
-
Patent number: 8673612Abstract: The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.Type: GrantFiled: October 25, 2001Date of Patent: March 18, 2014Assignee: L'Universite Pierre et Marie CurieInventors: David Klatzmann, Jean-Loup Salzmann, Bertrand Bellier, Charlotte Frisen, François-Loïc Cosset
-
Publication number: 20140023675Abstract: The present invention relates to polysaccharides selected from sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans intended to be used as a drug for the preventive or curative treatment of an influenza virus, as well as to the pharmaceutical compositions including, in particular in combination with at least one pharmaceutically acceptable carrier: either an extract of Codium fragile, including sulphated arabinogalactans, or an extract of Zostera marina or Lemna minor, including apiogalacturonans, or an extract of Caulerpa racemosa, including sulphated heteroglycans.Type: ApplicationFiled: January 3, 2012Publication date: January 23, 2014Applicants: Elicityl, Commissariat A L'Energie Atomique Et Aux Energies Alternatives (CEA), Institut National De La Sante Et De La Recherche Medicale - I.N.S.E.R.M., Centre National De La Recherche ScientifiqueInventors: Bruno Lina, Olivier Ferraris, Ho Hong Hai Vo, Francois-Loic Cosset, Judit Szecsi, Alain Heyraud, Hugues Lortat-Jacob, Julia Bartoli, Rabia Sadir, Thierry Livache, Benoit Darblade, Stephane Havet, Silvére Bonnet
-
Publication number: 20140017792Abstract: The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, and a second protein which comprises a ligand of the c-Kit receptor.Type: ApplicationFiled: June 10, 2013Publication date: January 16, 2014Inventors: Francois-Loic COSSET, Els Verhoeyen, Caroline Costa, Cecilia Frecha
-
Publication number: 20140004089Abstract: A method is provided for producing a recombinant pseudotyped viral vector particle wherein a cell is transfecting with (i) at least one vector construct; (ii) at least one packaging construct; and (iii) an expression construct encoding a chimeric glycoprotein encoded by a nucleic acid comprising the sequence of SEQ ID NO: 1 to yield a producer cell, followed by culturing the producer cell in a medium; and separating the producer cell from the medium to recover the recombinant viral vector particle from the medium. Vectors obtained in this manner have significantly higher titers than vectors coated with the parental non-chimeric glycoprotein.Type: ApplicationFiled: November 14, 2012Publication date: January 2, 2014Inventors: Didier TRONO, Francois-Loic Cosset, Virginie Sandrin
-
Patent number: 8557573Abstract: The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: —a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, and —a second protein which comprises a ligand of the c-Kit receptor.Type: GrantFiled: July 23, 2008Date of Patent: October 15, 2013Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm)Inventors: François-Loïc Cosset, Els Verhoeyen, Caroline Costa, Cecilia Frecha
-
Patent number: 8338168Abstract: The present invention provides improved chimeric glycoproteins (GPs) and improved lentiviral vectors pseudotyped with those glycoproteins. Also provided are methods and compositions for making such glycoproteins and vectors, and improved methods of in vitro and in vivo transduction of cells with such vectors. Improved chimeric GPs encode the extracellular and transmembrane domains of GALV or RD114 GPs fused to the cytoplasmic tail of MLV-A GP. Vectors pseudotyped with these GAL V/TR and RD 114/TR GP chimeras have significantly higher titers than vectors coated with the parental GPs. Additionally, RD114/TR-pseudotyped vectors are efficiently concentrated and are resistant to inactivation induced by the complement of both human and macaque sera. RD114 GP-pseudotyped lentiviral vectors have particular utility for in vivo gene transfer applications.Type: GrantFiled: April 25, 2003Date of Patent: December 25, 2012Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Clayton de la RechercheInventors: Didier Trono, Francois-Loic Cosset, Virginie Sandrin, Bertrand Boson, Didier Negre, Patrick Salmon